Acute Ischemic Stroke
Conditions
Interventions
butylphthalide in thrombolytic patients:Injection of butylphthalide for 7 days followed by taking butylphthalide capsules for 14 days in thromblytic patients
Non-butylphthalide in thrombolytic patients:Conventional treatment without butylphthalide in thromblytic patients
butylphthalide in non-thrombolytic patients:Injection of butylphthalide for 7 days followed by taking butylphthalide capsules for 14 days in non-thromblytic patients
Non-butylphthalide in non-thrombolytic patients:Conventional treatment without butylphthalide in non-thromblytic patients
Sponsors
Department of Neurology, Shanghai Tenth People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Patient's age is >= 18 years; 2. Patients presenting with anterior circulation acute ischemic stroke with neurology impairment, and time from onset to enrollment is less than 24h; 3. First stroke or Pre-stroke mRS score of 1.2, penumbra volume < 70ml; 6. Informed consent was obtained from patients; 7. Butylphthalide have to be started in the treatment group within 2 hours after randomization.
Exclusion criteria
Exclusion criteria: 1. The patients with intracranial hemorrhagic diseases seen by CT; 2. Patients with posterior circulation cerebral infarction; 3. Patients with bleeding prone diseases; 4. Patients with liver and kidney dysfunction; 5. Patients complicated with malignant tumor or undergoing anti-tumor therapy; 6. Patients with allergic constitution are allergic to celery and butylphthalide; 7. Patients with heart failure and multiple system failure; 8. Pregnant or lactating women; 9. Patients with dementia or mental problems who cannot cooperate with follow-up; 10. Patients with claustrophobia and metal implants who cannot be examined by cranial MRI; 11. Patients who plan to take thrombus by pulse; 12. Patients who have participated in other clinical trials now or in the past 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement of reperfusion volume in acute cerebral infarction;Increased infarct core volume;Proportion of symptomatic hemorrhagic transformation; | — |
Secondary
| Measure | Time frame |
|---|---|
| Proportion of patients with mRS score =2;NIHSS score improvement rate at day 90;mortality in day 90; | — |
Countries
China
Contacts
Public ContactXueyuan Liu
The Tenth Affiliated People's Hospital of Tongji University
Outcome results
None listed